- Home
- MGNX
MGNX
MacroGenics Inc.
as 03-13-2025 4:00pm EST
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | Rockville |
| Market Cap: | 151.9M | IPO Year: | 2013 |
| Target Price: | $7.17 | AVG Volume (30 days): | 551.0K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $19.54 | Next Earning Date: | 05-08-2025 |
| Revenue: | $141,329,000 | Revenue Growth: | 16.68% |
| Revenue Growth (this year): | 177.84% | Revenue Growth (next year): | -56.30% |
Stock Insider Trading Activity of MacroGenics Inc. (MGNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Beth Ann | MGNX | VP, Controller & Treasurer | Feb 15 '25 | Sell | $2.56 | 423 | $1,082.88 | 9,532 |
Latest MacroGenics Inc. News
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
GlobeNewswire
15 days ago
MacroGenics to Participate in Upcoming Investor Conferences
Simply Wall St.
18 days ago
Discovering US Penny Stocks In February 2025
Simply Wall St.
25 days ago
The past year for MacroGenics (NASDAQ:MGNX) investors has not been profitable
Simply Wall St.
2 months ago
3 US Penny Stocks With At Least $80M Market Cap
GlobeNewswire
3 months ago
MacroGenics to Participate in Upcoming Investor Conference
Simply Wall St.
3 months ago
US Penny Stocks To Watch In December 2024
MT Newswires
4 months ago
JMP Securities Downgrades MacroGenics to Market Perform
Compare MGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.